The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition.
Longeveron's Phase 2a CLEAR MIND trial demonstrated that laromestrocel (formerly Lomecel-B) is safe and well-tolerated in patients with mild Alzheimer's disease, with no reported cases of amyloid-related imaging abnormalities.
Longeveron's Phase 2b ELPIS II trial for Lomecel-B in Hypoplastic Left Heart Syndrome has reached 90% enrollment, with completion expected in Q2 2025 and potential BLA submission in 2026.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.